{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:07:13Z","timestamp":1793891233860,"version":"4.8.0"},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["#R01AG083740"],"award-info":[{"award-number":["#R01AG083740"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["#P30AG066507"],"award-info":[{"award-number":["#P30AG066507"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["#U19AG033655"],"award-info":[{"award-number":["#U19AG033655"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer\u2019s Association","doi-asserted-by":"publisher","award":["#SG-23-1061717"],"award-info":[{"award-number":["#SG-23-1061717"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer\u2019s Association","doi-asserted-by":"publisher","award":["ALZSI-26-1523522"],"award-info":[{"award-number":["ALZSI-26-1523522"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003792","name":"Swedish Brain Foundation","doi-asserted-by":"publisher","award":["#FO2024-0284"],"award-info":[{"award-number":["#FO2024-0284"]}],"id":[{"id":"10.13039\/501100003792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003792","name":"Swedish Brain Foundation","doi-asserted-by":"publisher","award":["FO2025-0055"],"award-info":[{"award-number":["FO2025-0055"]}],"id":[{"id":"10.13039\/501100003792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009750","name":"Kamprad Foundation","doi-asserted-by":"publisher","award":["#20243058"],"award-info":[{"award-number":["#20243058"]}],"id":[{"id":"10.13039\/501100009750","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Family R\u00f6nstr\u00f6m","award":["#FRS-0011"],"award-info":[{"award-number":["#FRS-0011"]}]},{"name":"Family R\u00f6nstr\u00f6m","award":["FRS-0004"],"award-info":[{"award-number":["FRS-0004"]}]},{"name":"Family R\u00f6nstr\u00f6m","award":["FRS-0013"],"award-info":[{"award-number":["FRS-0013"]}]},{"name":"Swedish Alzheimer Foundation","award":["#AF-1011949"],"award-info":[{"award-number":["#AF-1011949"]}]},{"name":"Swedish Alzheimer Foundation","award":["AF-1011799"],"award-info":[{"award-number":["AF-1011799"]}]},{"name":"Lilly Research Award Program"},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation","doi-asserted-by":"publisher","award":["MJFF-025507"],"award-info":[{"award-number":["MJFF-025507"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation","doi-asserted-by":"publisher","award":["2022-Projekt0107"],"award-info":[{"award-number":["2022-Projekt0107"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021728","name":"Bundy Academy and MultiPark","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021728","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003252","name":"Lund University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006775","name":"GE Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006775","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Blood biomarkers have the potential to revolutionize Alzheimer's disease diagnosis, offering advantages over CSF and PET due to their accessibility, scalability and cost-effectiveness. This study evaluated the effectiveness of individual plasma biomarkers, such as phosphorylated Tau (pTau) 217, as well as biomarker combinations, with a focus on the pTau 217\/\u03b2-Amyloid (A\u03b2) 1\u201342 ratio to predict amyloid positivity. To improve clinical utility, a dual threshold approach was applied to maximize predictive values and positive likelihood ratios while minimizing the proportion of indeterminate results.<\/jats:p>\n                  <jats:p>Plasma samples from 208 participants (including seven with subjective cognitive decline, 150 with mild cognitive impairment, 12 with Alzheimer's disease dementia and 39 with other cognitive conditions) from three cohorts (BioFINDER2, BIOCARD and MissionAD) were analysed to measure A\u03b21\u201342, A\u03b21\u201340 and pTau217 levels using the Fujirebio LUMIPULSE\u00ae G1200 platform. Amyloid status was determined by FDA-cleared PET imaging and\/or CSF biomarker ratios. Logistic regression modelling evaluated biomarkers either individually or in combination to identify those that best distinguished amyloid positivity. Clinically applicable thresholds were established through likelihood ratio analysis and further evaluated based on predictive values.<\/jats:p>\n                  <jats:p>When assessing the ability of individual plasma biomarkers to differentiate between amyloid-positive and amyloid-negative participants, plasma pTau217 (P &amp;lt; 0.001) and plasma A\u03b21\u201342 (P = 0.0056) demonstrated significant discriminative power, whereas A\u03b21\u201340 (P = 0.30) did not. Notably, the integration of these biomarkers into the plasma pTau217\/A\u03b21\u201342 ratio demonstrated enhanced classification performance (P &amp;lt; 0.001). Using a two-threshold approach based on positive and negative likelihood ratios (PLR\/NLR) targets of 14\/20, respectively, the plasma pTau217\/A\u03b21\u201342 ratio achieved a positive predictive value (PPV) of 94.44% and negative predictive value (NPV) of 94.28%, in the parametric model, comparable to plasma pTau217 alone (PPV: 94.44%, NPV: 94.28%), but yielded fewer indeterminate results (26.5% versus 38.6%). Using a non-parametric model, the plasma ratio achieved a PPV and NPV of 94.62% and 91.78%, respectively, while plasma pTau217 alone achieved 92.41% and 92.86%; the ratio once again reduced the proportion of indeterminate results (20.2% versus 35.1%).<\/jats:p>\n                  <jats:p>The plasma pTau217\/A\u03b21\u201342 ratio demonstrated superior performance in identifying amyloid pathology and reduced the frequency of indeterminate results compared to plasma pTau217 alone. These findings support the evaluation of the clinical utility of the plasma pTau217\/A\u03b21\u201342 ratio as a tool for identifying amyloid pathology in patients presenting with cognitive complaints.<\/jats:p>","DOI":"10.1093\/brain\/awag001","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T12:31:47Z","timestamp":1767702707000},"page":"1168-1181","source":"Crossref","is-referenced-by-count":15,"title":["Plasma pTau 217\/\u03b2-amyloid 1\u201342 ratio for enhanced accuracy and reduced uncertainty in detecting amyloid pathology"],"prefix":"10.1093","volume":"149","author":[{"given":"Natalya","family":"Benina","sequence":"first","affiliation":[{"name":"Fujirebio Diagnostics, Inc. , Malvern, PA 19355 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luna","family":"Buitrago","sequence":"additional","affiliation":[{"name":"Fujirebio Diagnostics, Inc. , Malvern, PA 19355 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca I","family":"De Simone","sequence":"additional","affiliation":[{"name":"Fujirebio Diagnostics, Inc. , Malvern, PA 19355 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel R","family":"Radwan","sequence":"additional","affiliation":[{"name":"Fujirebio Diagnostics, Inc. , Malvern, PA 19355 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Craig","family":"Miller","sequence":"additional","affiliation":[{"name":"Fujirebio Diagnostics, Inc. , Malvern, PA 19355 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Martin","sequence":"additional","affiliation":[{"name":"Fujirebio Diagnostics, Inc. , Malvern, PA 19355 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Dickson","sequence":"additional","affiliation":[{"name":"Fujirebio Diagnostics, Inc. , Malvern, PA 19355 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Ho","sequence":"additional","affiliation":[{"name":"Department of Neurology, Johns Hopkins School of Medicine , Baltimore, MD 21205 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhay","family":"Moghekar","sequence":"additional","affiliation":[{"name":"Department of Neurology, Johns Hopkins School of Medicine , Baltimore, MD 21205 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilyn","family":"Albert","sequence":"additional","affiliation":[{"name":"Department of Neurology, Johns Hopkins School of Medicine , Baltimore, MD 21205 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8885-7724","authenticated-orcid":false,"given":"Niklas","family":"Mattsson-Carlgren","sequence":"additional","affiliation":[{"name":"Clinical Memory Research Unit, Department of Clinical Sciences Malm\u00f6, Lund University , Lund 221 00 ,","place":["Sweden"]},{"name":"Memory Clinic, Skane University Hospital , Malm\u00f6 205 02 ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9267-1930","authenticated-orcid":false,"given":"Sebastian","family":"Palmqvist","sequence":"additional","affiliation":[{"name":"Clinical Memory Research Unit, Department of Clinical Sciences Malm\u00f6, Lund University , Lund 221 00 ,","place":["Sweden"]},{"name":"Memory Clinic, Skane University Hospital , Malm\u00f6 205 02 ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rik","family":"Ossenkoppele","sequence":"additional","affiliation":[{"name":"Clinical Memory Research Unit, Department of Clinical Sciences Malm\u00f6, Lund University , Lund 221 00 ,","place":["Sweden"]},{"name":"VU University Medical Center, Department of Neurology and Alzheimer Center, Amsterdam Neuroscience , Amsterdam 1081 HV ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus F\u00f6rnvik","family":"Jonsson","sequence":"additional","affiliation":[{"name":"Department of Clinical Chemistry and Pharmacology, Sk\u00e5ne University Hospital , Lund 221 85 ,","place":["Sweden"]},{"name":"Section for Clinical Chemistry, Department of Translational Medicine, Lund University , Malm\u00f6 205 02 ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8467-7286","authenticated-orcid":false,"given":"Oskar","family":"Hansson","sequence":"additional","affiliation":[{"name":"Clinical Memory Research Unit, Department of Clinical Sciences Malm\u00f6, Lund University , Lund 221 00 ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Stomrud","sequence":"additional","affiliation":[{"name":"Clinical Memory Research Unit, Department of Clinical Sciences Malm\u00f6, Lund University , Lund 221 00 ,","place":["Sweden"]},{"name":"Memory Clinic, Skane University Hospital , Malm\u00f6 205 02 ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pallavi","family":"Sachdev","sequence":"additional","affiliation":[{"name":"Eisai Inc. , Nutley, NJ 07110 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Niu","sequence":"additional","affiliation":[{"name":"Eisai Inc. , Nutley, NJ 07110 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Verbel","sequence":"additional","affiliation":[{"name":"Eisai Inc. , Nutley, NJ 07110 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas M","family":"Hawkins","sequence":"additional","affiliation":[{"name":"School of Statistics, University of Minnesota , Minneapolis, MN 55455 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"key":"2026040804073922500_awag001-B1","doi-asserted-by":"crossref","first-page":"111","DOI":"10.31887\/DCNS.2009.11.2\/cqiu","article-title":"Epidemiology of Alzheimer\u2019s disease: Occurrence, determinants, and strategies toward intervention","volume":"11","author":"Qiu","year":"2009","journal-title":"Dialogues Clin Neurosci"},{"key":"2026040804073922500_awag001-B2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the national institute on aging-Alzheimer\u2019s association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"key":"2026040804073922500_awag001-B3","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research framework: Toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"key":"2026040804073922500_awag001-B4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/cshperspect.a006189","article-title":"Neuropathological alterations in Alzheimer disease","volume":"1","author":"Serrano-Pozo","year":"2011","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2026040804073922500_awag001-B5","first-page":"1","article-title":"Neuropathology of the Alzheimer\u2019s continuum: An update","volume":"1","author":"Jellinger","year":"2020","journal-title":"Free Neuropathol"},{"key":"2026040804073922500_awag001-B6","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13024-019-0333-5","article-title":"The neuropathological diagnosis of Alzheimer\u2019s disease","volume":"14","author":"DeTure","year":"2019","journal-title":"Mol Neurodegener"},{"key":"2026040804073922500_awag001-B7","first-page":"36","article-title":"Preclinical, prodromal, and dementia stages of Alzheimer\u2019s disease","volume":"15","author":"Scharre","year":"2019","journal-title":"Pract Neurol"},{"key":"2026040804073922500_awag001-B8","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/alz.12447","article-title":"Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer\u2019s disease","volume":"18","author":"Chatterjee","year":"2022","journal-title":"Alzheimers Dement"},{"key":"2026040804073922500_awag001-B9","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1093\/brain\/awx243","article-title":"Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer\u2019s disease","volume":"140","author":"Bejanin","year":"2017","journal-title":"Brain"},{"key":"2026040804073922500_awag001-B10","doi-asserted-by":"crossref","first-page":"771","DOI":"10.14283\/jpad.2023.123","article-title":"Lecanemab clarity AD: Quality-of-life results from a randomized, double-blind phase 3 trial in early Alzheimer\u2019s disease","volume":"10","author":"Cohen","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"key":"2026040804073922500_awag001-B11","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"2026040804073922500_awag001-B12","doi-asserted-by":"crossref","first-page":"8216","DOI":"10.1002\/alz.14184","article-title":"Recommendations for clinical implementation of blood-based biomarkers for Alzheimer\u2019s disease","volume":"20","author":"Mielke","year":"2024","journal-title":"Alzheimers Dement"},{"key":"2026040804073922500_awag001-B13","doi-asserted-by":"crossref","first-page":"356","DOI":"10.14283\/jpad.2023.30","article-title":"Lecanemab: Appropriate use recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"key":"2026040804073922500_awag001-B14","doi-asserted-by":"crossref","first-page":"13S","DOI":"10.2967\/jnumed.121.263195","article-title":"The role of amyloid PET in imaging neurodegenerative disorders: A review","volume":"63","author":"Chapleau","year":"2022","journal-title":"J Nucl Med"},{"key":"2026040804073922500_awag001-B15","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.jalz.2018.07.220","article-title":"Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer\u2019s disease","volume":"14","author":"Shaw","year":"2018","journal-title":"Alzheimers Dement"},{"key":"2026040804073922500_awag001-B16","doi-asserted-by":"crossref","first-page":"426","DOI":"10.14283\/jpad.2023.43","article-title":"Diagnostic biomarkers of amyloid and tau pathology in Alzheimer\u2019s disease: An overview of tests for clinical practice in the United States and Europe","volume":"10","author":"Iaccarino","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"key":"2026040804073922500_awag001-B17","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1016\/j.neuron.2023.05.017","article-title":"Blood-based biomarkers for Alzheimer\u2019s disease: Current state and future use in a transformed global healthcare landscape","volume":"111","author":"Hampel","year":"2023","journal-title":"Neuron"},{"key":"2026040804073922500_awag001-B18","doi-asserted-by":"crossref","first-page":"371","DOI":"10.14283\/jpad.2021.23","article-title":"Diagnosis of early Alzheimer\u2019s disease: Clinical practice in 2021","volume":"8","author":"Porsteinsson","year":"2021","journal-title":"J Prev Alzheimers Dis"},{"key":"2026040804073922500_awag001-B19","doi-asserted-by":"crossref","first-page":"158","DOI":"10.14245\/kjs.2017.14.4.158","article-title":"Iatrogenic spinal subarachnoid hematoma after diagnostic lumbar puncture","volume":"14","author":"Park","year":"2017","journal-title":"Korean J Spine"},{"key":"2026040804073922500_awag001-B20","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","article-title":"Biomarkers for neurodegenerative diseases","volume":"27","author":"Hansson","year":"2021","journal-title":"Nat Med"},{"key":"2026040804073922500_awag001-B21","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature25456","article-title":"High performance plasma amyloid-\u03b2 biomarkers for Alzheimer\u2019s disease","volume":"554","author":"Nakamura","year":"2018","journal-title":"Nature"},{"key":"2026040804073922500_awag001-B22","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/s41591-022-01822-2","article-title":"Performance of plasma phosphorylated tau 181 and 217 in the community","volume":"28","author":"Mielke","year":"2022","journal-title":"Nat Med"},{"key":"2026040804073922500_awag001-B23","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/joim.13332","article-title":"Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer\u2019s disease","volume":"290","author":"Alawode","year":"2021","journal-title":"J Intern Med"},{"key":"2026040804073922500_awag001-B24","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41582-024-00977-5","article-title":"Acceptable performance of blood biomarker tests of amyloid pathology \u2014 Recommendations from the Global CEO Initiative on Alzheimer\u2019s Disease","volume":"20","author":"Schindler","year":"2024","journal-title":"Nat Rev Neurol"},{"key":"2026040804073922500_awag001-B25","doi-asserted-by":"crossref","first-page":"569","DOI":"10.14283\/jpad.2022.85","article-title":"Blood biomarkers from research use to clinical practice: What must be done? A report from the EU\/US CTAD task force","volume":"9","author":"Angioni","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"key":"2026040804073922500_awag001-B26","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/s43587-023-00403-3","article-title":"Blood biomarkers for Alzheimer's disease in clinical practice and trials","volume":"3","author":"Hansson","year":"2023","journal-title":"Nat Aging"},{"key":"2026040804073922500_awag001-B27","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/s43587-023-00471-5","article-title":"A two-step workflow based on plasma p-tau217 to screen for amyloid \u03b2 positivity with further confirmatory testing only in uncertain cases","volume":"3","author":"Brum","year":"2023","journal-title":"Nat Aging"},{"key":"2026040804073922500_awag001-B28","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jamaneurol.2023.4596","article-title":"Plasma biomarker strategy for selecting patients with Alzheimer disease for antiamyloid immunotherapies","volume":"81","author":"Mattsson-Carlgren","year":"2024","journal-title":"JAMA Neurol"},{"key":"2026040804073922500_awag001-B29","doi-asserted-by":"crossref","first-page":"6506","DOI":"10.1002\/alz.14140","article-title":"Optimizing cutpoints for clinical interpretation of brain amyloid status using plasma p-tau217 immunoassays","volume":"20","author":"Figdore","year":"2024","journal-title":"Alzheimers Dement"},{"key":"2026040804073922500_awag001-B30","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1002\/alz.12756","article-title":"The Alzheimer\u2019s association appropriate use recommendations for blood biomarkers in Alzheimer\u2019s disease","volume":"18","author":"Hansson","year":"2022","journal-title":"Alzheimers Dement"},{"key":"2026040804073922500_awag001-B31","doi-asserted-by":"crossref","first-page":"e70081","DOI":"10.1002\/dad2.70081","article-title":"Plasma biomarker trajectories: Impact of AD genetic risk and clinical progression","volume":"17","author":"Pettigrew","year":"2025","journal-title":"Alzheimers Dement (Amst)"},{"key":"2026040804073922500_awag001-B32","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1001\/jama.2024.13855","article-title":"Blood biomarkers to detect Alzheimer disease in primary care and secondary care","volume":"332","author":"Palmqvist","year":"2024","journal-title":"JAMA"},{"key":"2026040804073922500_awag001-B33","doi-asserted-by":"crossref","first-page":"218","DOI":"10.14283\/jpad.2021.4","article-title":"Amyloid and APOE status of screened subjects in the Elenbecestat MissionAD phase 3 program","volume":"8","author":"Roberts","year":"2021","journal-title":"J Prev Alzheimers Dis"},{"key":"2026040804073922500_awag001-B34","doi-asserted-by":"crossref","first-page":"578753","DOI":"10.3389\/fneur.2020.578753","article-title":"Quantitative evaluation of 18F-flutemetamol PET in patients with cognitive impairment and suspected Alzheimer\u2019s disease: A multicenter study","volume":"11","author":"Matsuda","year":"2021","journal-title":"Front Neurol"},{"key":"2026040804073922500_awag001-B35","doi-asserted-by":"crossref","first-page":"70","DOI":"10.2967\/jnumed.112.109009","article-title":"Amyloid-\u03b2 imaging with Pittsburgh compound B and florbetapir: Comparing radiotracers and quantification methods","volume":"54","author":"Landau","year":"2013","journal-title":"J Nucl Med"},{"key":"2026040804073922500_awag001-B36","author":"Roche Diagnostics"},{"key":"2026040804073922500_awag001-B37","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1002\/alz.13721","article-title":"Importance of cerebrospinal fluid (CSF) collection protocol for the accurate diagnosis of Alzheimer\u2019s disease when using CSF biomarkers","volume":"20","author":"Algeciras-Schimnich","year":"2024","journal-title":"Alzheimers Dement"},{"key":"2026040804073922500_awag001-B38","author":"Sha"},{"key":"2026040804073922500_awag001-B39","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1093\/jalm\/jfad109","article-title":"A quantile-quantile toolbox for reference intervals","volume":"9","author":"Hawkins","year":"2024","journal-title":"J Appl Lab Med"},{"key":"2026040804073922500_awag001-B40","volume-title":"Applied linear regression","author":"Weisberg","year":"2014"},{"key":"2026040804073922500_awag001-B41","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1038\/s41591-025-03622-w","article-title":"Plasma phospho-Tau217 for Alzheimer\u2018s disease diagnosis in primary and secondary care using a fully automated platform","volume":"31","author":"Palmqvist","year":"2025","journal-title":"Nat Med"},{"key":"2026040804073922500_awag001-B42","first-page":"29","volume-title":"The patient history: evidence-based approach","author":"Davis","year":"2005"},{"key":"2026040804073922500_awag001-B43","first-page":"1","article-title":"Diagnostic performance of plasma pTau217, pTau181, A\u03b21-42 and A\u03b21-40 in the LUMIPULSE automated platform for the detection of Alzheimer disease","volume":"16","author":"Arranz","year":"2024","journal-title":"Alzheimers Res Ther"},{"key":"2026040804073922500_awag001-B44","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13195-025-01719-5","article-title":"Diagnostic performance of plasma p-tau217 in a memory clinic cohort using the Lumipulse automated platform","volume":"17","author":"Mart\u00ednez-Dubarbie","year":"2025","journal-title":"Alzheimers Res Ther"},{"key":"2026040804073922500_awag001-B45","first-page":"1","article-title":"Diagnostic accuracy of plasma p-tau217\/A\u03b242 for Alzheimer\u2019s disease in clinical and community cohorts","volume":"21","author":"Wang","year":"2025","journal-title":"Alzheimers Dement"},{"key":"2026040804073922500_awag001-B46","doi-asserted-by":"crossref","first-page":"105405","DOI":"10.1016\/j.ebiom.2024.105405","article-title":"Detection and staging of Alzheimer\u2019s disease by plasma pTau217 on a high throughput immunoassay platform","volume":"109","author":"Feizpour","year":"2024","journal-title":"eBioMedicine"},{"key":"2026040804073922500_awag001-B47","doi-asserted-by":"crossref","first-page":"5805","DOI":"10.1002\/alz.13455","article-title":"The potential clinical value of plasma biomarkers in Alzheimer\u2019s disease","volume":"19","author":"Blennow","year":"2023","journal-title":"Alzheimers Dement"},{"key":"2026040804073922500_awag001-B48","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1093\/brain\/aww015","article-title":"Cerebrospinal fluid analysis detects cerebral amyloid-\u03b2 accumulation earlier than positron emission tomography","volume":"139","author":"Palmqvist","year":"2016","journal-title":"Brain"},{"key":"2026040804073922500_awag001-B49","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/brain\/awu367","article-title":"Independent information from cerebrospinal fluid amyloid-\u03b2 and florbetapir imaging in Alzheimer\u2019s disease","volume":"138","author":"Mattsson","year":"2015","journal-title":"Brain"},{"key":"2026040804073922500_awag001-B50","doi-asserted-by":"crossref","first-page":"8074","DOI":"10.1002\/alz.14315","article-title":"Head-to-head comparison of leading blood tests for Alzheimer\u2019s disease pathology","volume":"20","author":"Schindler","year":"2024","journal-title":"Alzheimers Dement"},{"key":"2026040804073922500_awag001-B51","doi-asserted-by":"crossref","first-page":"e70469","DOI":"10.1002\/alz.70469","article-title":"Comparison of plasma p-tau217\/A\u03b242, p-tau217, and A\u03b242\/A\u03b240 biomarkers by race to detect Alzheimer\u2019s disease","volume":"21","author":"Cousins","year":"2025","journal-title":"Alzheimers Dement"},{"key":"2026040804073922500_awag001-B52","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jamaneurol.2023.4719","article-title":"Effect of Neprilysin inhibition on Alzheimer disease plasma biomarkers: A secondary analysis of a randomized clinical trial","volume":"81","author":"Brum","year":"2024","journal-title":"JAMA Neurol"}],"container-title":["Brain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/brain\/advance-article-pdf\/doi\/10.1093\/brain\/awag001\/66509187\/awag001.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/149\/4\/1168\/66509187\/awag001.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/149\/4\/1168\/66509187\/awag001.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T08:07:53Z","timestamp":1775635673000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/brain\/article\/149\/4\/1168\/8435032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":52,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,1,21]]},"published-print":{"date-parts":[[2026,4,7]]}},"URL":"https:\/\/doi.org\/10.1093\/brain\/awag001","relation":{},"ISSN":["0006-8950","1460-2156"],"issn-type":[{"value":"0006-8950","type":"print"},{"value":"1460-2156","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,1,21]]}}}